Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises AstraZeneca on the sale of a pharmaceutical portfolio
Mandate

Vinge advises AstraZeneca on the sale of a pharmaceutical portfolio

June 04, 2007

Vinge is advising AstraZeneca on the sale of a large number of pharmaceuticals to Recip AB. The sale includes a portfolio of infection drugs for sale in Sweden, Norway, Denmark and Iceland. The annual sales of the 17 drugs included in the portfolio are SEK 240 million.

AstraZeneca is represented by partner Malin Leffler, assisted by Anna Berntsson and Claes Henriksson.

Related

Vinge advises as Nimlas expands with dual acquisitions in the electrical sector

 Vinge has advised Nimlas in connection with the acquisitions of Uppsala Elcentral AB and Tjädermo's El AB – two strategic transactions that strengthen the group's position in the Swedish electrical installation market.
February 20, 2026

Vinge advises Zengun in connection with its issuance of bonds in an amount of SEK 750 million and its early redemption of outstanding bonds

 Vinge has advised Zengun Group AB (publ) in connection with its issuance of senior secured bonds in an amount of SEK 750 million (within a framework of SEK 1,500 million) and in parallel with the company's voluntary early redemption of previously issued bonds.
February 20, 2026

Vinge has advised Sluta Gräva in connection with its acquisition of Stavrex

 Vinge has advised Sluta Gräv, a portfolio company of Sobro, in connection with the acquisition of Stavrex. Together, the companies form the Nordic region’s leading supplier of ground screws, with the market’s broadest offering.
February 18, 2026